Latest news with #LuisSanay
Yahoo
07-05-2025
- Business
- Yahoo
Novavax to Participate in BofA Securities 2025 Health Care Conference
GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at A replay of the webcast will be available for 30 days. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit and LinkedIn for more information. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler 202-709-5563 media@ Novavax Logo (PRNewsfoto/Novavax) Cision View original content to download multimedia: SOURCE Novavax, Inc.
Yahoo
01-05-2025
- Business
- Yahoo
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details:Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: Dial-in number: (800) 836-8184 (Domestic) or(+1) (646) 357-8785 (International) Webcast: Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back. Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call. To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time. Replay details:Date: Available starting at 11:30 a.m. U.S. ET, May 8, 2025, until 11:59 p.m. U.S. ET, May 15, 2025 Dial-in number: (888) 660-6345 (Domestic) or(+1) (646) 517-4150 (International) Passcode: 88407# Webcast: until June 7, 2025 About NovavaxNovavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit and LinkedIn for more information. Contacts: Investors Luis Sanay, CFA240-268-2022ir@ MediaGiovanna Chandler202-709-5563media@ View original content to download multimedia: SOURCE Novavax, Inc. Sign in to access your portfolio
